Amedeo Smart

Free Medical Literature Service

 

Amedeo

Breast Cancer
  Free Subscription

Articles published in
Breast Cancer
    April 2024
  1. TOKUDA PJK, Mitsuyoshi T, Ono Y, Kishi T, et al
    Acute adverse events of ultra-hypofractionated whole-breast irradiation after breast-conserving surgery for early breast cancer in Japan: an interim analysis of the multi-institutional phase II UPBEAT study.
    Breast Cancer. 2024 Apr 12. doi: 10.1007/s12282-024-01577.
    >> Share

  2. DE MOURA A, Loirat D, Vaillant S, Korbi S, et al
    Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases.
    Breast Cancer. 2024 Apr 10. doi: 10.1007/s12282-024-01565.
    >> Share

  3. SUZUKI K, Morishita S, Nakano J, Okayama T, et al
    Association between quality of life and mortality risk in patients with breast cancer: a systematic review and meta-analysis.
    Breast Cancer. 2024 Apr 9. doi: 10.1007/s12282-024-01581.
    >> Share

  4. WATANABE A, Tsunashima R, Kato C, Kitano S, et al
    Investigation of recurrence prediction ability of EndoPredict((R)) using microarray data from fresh frozen tissues in ER-positive, HER2-negative breast cancer and indication expansion of EndoPredict((R)) from microarray data from fresh-frozen to FFPE
    Breast Cancer. 2024 Apr 8. doi: 10.1007/s12282-024-01573.
    >> Share

  5. YOSHIMURA M, Yamauchi C, Sanuki N, Hamamoto Y, et al
    The Japanese breast cancer society clinical practice guidelines for radiation treatment of breast cancer, 2022 edition.
    Breast Cancer. 2024 Apr 5. doi: 10.1007/s12282-024-01568.
    >> Share

  6. YAMAMOTO Y, Yamauchi C, Toyama T, Nagai S, et al
    The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment.
    Breast Cancer. 2024 Apr 3. doi: 10.1007/s12282-024-01566.
    >> Share

  7. LIN D, Sturgeon KM, Muscat JE, Zhou S, et al
    Associations of pre-diagnosis physical activity with treatment tolerance and treatment efficacy in breast cancer patients with neoadjuvant chemotherapy.
    Breast Cancer. 2024 Apr 2. doi: 10.1007/s12282-024-01569.
    >> Share

  8. YE JH, Yu J, Huang MY, Mo YM, et al
    The correlation study between TOP2A gene expression in circulating tumor cells and chemotherapeutic drug resistance of patients with breast cancer.
    Breast Cancer. 2024 Apr 1. doi: 10.1007/s12282-024-01553.
    >> Share

    March 2024
  9. OCHIYA T, Hashimoto K, Shimomura A
    Prospects for liquid biopsy using microRNA and extracellular vesicles in breast cancer.
    Breast Cancer. 2024 Mar 30. doi: 10.1007/s12282-024-01563.
    >> Share

  10. NARUI K, Satake T, Ishikawa T, Muto M, et al
    Endoscopic mastectomy followed by immediate breast reconstruction with fat grafting for breast cancer.
    Breast Cancer. 2024 Mar 21. doi: 10.1007/s12282-024-01561.
    >> Share

  11. HASHIMOTO K, Ochiya T, Shimomura A
    Liquid biopsy using non-coding RNAs and extracellular vesicles for breast cancer management.
    Breast Cancer. 2024 Mar 21. doi: 10.1007/s12282-024-01562.
    >> Share

  12. VO K, Ladbury C, Yoon S, Bazan J, et al
    Omission of adjuvant radiotherapy in low-risk elderly males with breast cancer.
    Breast Cancer. 2024 Mar 20. doi: 10.1007/s12282-024-01560.
    >> Share

  13. OHMURA H, Hanamura F, Okumura Y, Ando Y, et al
    Liquid biopsy for breast cancer and other solid tumors: a review of recent advances.
    Breast Cancer. 2024 Mar 16. doi: 10.1007/s12282-024-01556.
    >> Share

  14. HU X
    The role of the BTLA-HVEM complex in the pathogenesis of breast cancer.
    Breast Cancer. 2024 Mar 14. doi: 10.1007/s12282-024-01557.
    >> Share

  15. LI G, Lin X, Wang X, Cai L, et al
    Enhancing radiosensitivity in triple-negative breast cancer through targeting ELOB.
    Breast Cancer. 2024 Mar 12. doi: 10.1007/s12282-024-01554.
    >> Share

  16. KANG D, Park S, Kim HJ, Lee J, et al
    Comprehensive Young Age Breast Cancer registry from clinical, genomics, and patient-reported outcomes measured with 15 years follow-up: the CHARM cohort profile.
    Breast Cancer. 2024 Mar 12. doi: 10.1007/s12282-024-01559.
    >> Share

  17. KIDA K, Yamada A, Shimada K, Narui K, et al
    A prospective comparison study utilizing patient-reported outcomes of taxane-related peripheral neuropathy between nab-paclitaxel and standard paclitaxel in patients with breast cancer.
    Breast Cancer. 2024 Mar 8. doi: 10.1007/s12282-024-01551.
    >> Share

  18. OBA K, Adachi M, Kobayashi T, Takaya E, et al
    Deep learning model to predict Ki-67 expression of breast cancer using digital breast tomosynthesis.
    Breast Cancer. 2024 Mar 7. doi: 10.1007/s12282-024-01549.
    >> Share

  19. HATTORI M, Honma N, Nagai S, Narui K, et al
    Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast Cancer Society Clinical Practice Guidelines.
    Breast Cancer. 2024 Mar 4. doi: 10.1007/s12282-024-01550.
    >> Share

  20. KASAHARA M, Kanematsu S, Tanaka Y, Okazaki S, et al
    Clinical benefits of tomosynthesis-guided vacuum assisted breast biopsy: a comparison with stereotactic vacuum assisted biopsy.
    Breast Cancer. 2024;31:329-334.
    >> Share

  21. WU X, Gui Y, Liu J, Li S, et al
    Patient-reported outcomes of mesh in minimally invasive (laparoscopic/robot-assisted) immediate subpectoral prosthesis breast reconstruction: a retrospective study.
    Breast Cancer. 2024;31:243-251.
    >> Share

  22. WONG HH, Cojocaru E, Watkins J, James S, et al
    Radiation-induced angiosarcoma of the breast: retrospective analysis at a regional treatment centre.
    Breast Cancer. 2024;31:272-282.
    >> Share

  23. AOYAMA Y, Hoshino E, Shimomura A, Shimizu C, et al
    Reliability and validity of the Japanese version of the Chemotherapy-induced Alopecia Distress Scale.
    Breast Cancer. 2024;31:234-242.
    >> Share

  24. CHEN BF, Tsai YF, Lien PJ, Lin YS, et al
    Prevalent landscape of tumor genomic alterations of luminal B1 breast cancers using a comprehensive genomic profiling assay in Taiwan.
    Breast Cancer. 2024;31:217-227.
    >> Share

  25. NAKAMURA A, Ohnuki K, Takahashi H, Usami S, et al
    The effects of breast density on the benefits of mammograms with adjunctive ultrasonography in breast screening.
    Breast Cancer. 2024;31:228-233.
    >> Share

    February 2024
  26. PARIJA M, Prakash S, Krishna BM, Dash S, et al
    SIRT1 mediates breast cancer development and tumorigenesis controlled by estrogen-related receptor beta.
    Breast Cancer. 2024 Feb 29. doi: 10.1007/s12282-024-01555.
    >> Share

  27. KIM N, Cho WK, Park W, Lee JE, et al
    Outcomes of whole breast radiation therapy in Asian breast cancer patients with prior cosmetic implants.
    Breast Cancer. 2024 Feb 18. doi: 10.1007/s12282-024-01547.
    >> Share

  28. SATO K, Fuchikami H, Takeda N, Natsume N, et al
    Preliminary report on ultrashort perioperative partial-breast irradiation with multicatheter interstitial brachytherapy for early-stage breast cancer.
    Breast Cancer. 2024 Feb 15. doi: 10.1007/s12282-024-01546.
    >> Share

  29. HACKING SM, Windsor G, Cooper R, Jiao Z, et al
    A novel approach correlating pathologic complete response with digital pathology and radiomics in triple-negative breast cancer.
    Breast Cancer. 2024 Feb 13. doi: 10.1007/s12282-024-01544.
    >> Share

  30. IWAMOTO T, Kumamaru H, Niikura N, Sagara Y, et al
    Survival trends and patient characteristics between 2004 and 2016 for breast cancer in Japan based on the National Clinical Database-Breast Cancer Registry.
    Breast Cancer. 2024 Feb 6. doi: 10.1007/s12282-024-01545.
    >> Share

  31. YU T, Rui L, Jiumei Z, Ziwei L, et al
    Advances in the study of autophagy in breast cancer.
    Breast Cancer. 2024 Feb 5. doi: 10.1007/s12282-023-01541.
    >> Share

  32. ZHUANG JY, Huang ZN, Weng ZJ, Liu MM, et al
    Expression and clinical significance of hypoxia-induced long non-coding RNA TCONS_I2_00001955 in breast cancer.
    Breast Cancer. 2024 Feb 4. doi: 10.1007/s12282-023-01540.
    >> Share

    January 2024
  33. ZHENG H, Wu L, Chen J, Na N, et al
    Neoadjuvant nivolumab plus bevacizumab therapy improves the prognosis of triple-negative breast cancer in humanized mouse models.
    Breast Cancer. 2024 Jan 30. doi: 10.1007/s12282-024-01543.
    >> Share

  34. HOSHI N, Uemura T, Tachibana K, Abe S, et al
    Endosomal protein expression of gamma1-adaptin is associated with tumor growth activity and relapse-free survival in breast cancer.
    Breast Cancer. 2024 Jan 24. doi: 10.1007/s12282-023-01539.
    >> Share

  35. DING W, Ye D, Chen H, Lin Y, et al
    Clinicopathological differences and survival benefit in ER+/PR+/HER2+ vs ER+/PR-/HER2+ breast cancer subtypes.
    Breast Cancer. 2024 Jan 17. doi: 10.1007/s12282-023-01538.
    >> Share

  36. SAGARA Y, Kumamaru H, Niikura N, Miyashita M, et al
    2020 Annual Report of National Clinical Database-Breast Cancer Registry: 10-year mortality of elderly breast cancer patients in Japan.
    Breast Cancer. 2024 Jan 5. doi: 10.1007/s12282-023-01532.
    >> Share

  37. TAIRA N, Kikawa Y, Iwamoto T, Miyoshi Y, et al
    Pilot trial of an electronic patient-reported outcome monitoring system in patients with metastatic breast cancer undergoing chemotherapy.
    Breast Cancer. 2024 Jan 4. doi: 10.1007/s12282-023-01537.
    >> Share

  38. HORIMOTO Y
    Comment on 'An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers' by Fukui et al.
    Breast Cancer. 2024;31:154.
    >> Share

  39. YOSHIDA M, Yoshimura RI, Notake R, Shinjo H, et al
    Feasibility of accelerated partial breast irradiation with strut-adjusted volume implant brachytherapy in Japan focusing on dosimetry and acute toxicity: a Japanese multi-institutional prospective study.
    Breast Cancer. 2024;31:75-83.
    >> Share

    December 2023
  40. HONG YW, Kuo IM, Kuo WL, Yu CC, et al
    The influence of chronic renal insufficiency on multi-therapeutic modalities for breast cancer: a single-center experience.
    Breast Cancer. 2023 Dec 27. doi: 10.1007/s12282-023-01530.
    >> Share

  41. KAWAI M, Ohtani S, Iwasaki M, Yamamoto S, et al
    The Japanese Breast Cancer Society clinical practice guidelines for epidemiology and prevention of breast cancer, 2022 edition.
    Breast Cancer. 2023 Dec 26. doi: 10.1007/s12282-023-01531.
    >> Share

  42. KAZEMZADEH F, Snoek JAA, Voorham QJ, van Oijen MGH, et al
    Association of metastatic pattern in breast cancer with tumor and patient-specific factors: a nationwide autopsy study using artificial intelligence.
    Breast Cancer. 2023 Dec 22. doi: 10.1007/s12282-023-01534.
    >> Share

  43. KUBOTA K, Nakashima K, Nakashima K, Kataoka M, et al
    Correction: The Japanese breast cancer society clinical practice guidelines for breast cancer screening and diagnosis, 2022 edition.
    Breast Cancer. 2023 Dec 11. doi: 10.1007/s12282-023-01533.
    >> Share

  44. ALTUNDAG K
    Are breast cancer subtypes different in breast cancer patients with and without hepatitis C virus infection?
    Breast Cancer. 2023 Dec 9. doi: 10.1007/s12282-023-01536.
    >> Share

  45. MIYASHITA M, Kumamaru H, Niikura N, Sagara Y, et al
    Annual report of the Japanese Breast Cancer Registry for 2019.
    Breast Cancer. 2023 Dec 4. doi: 10.1007/s12282-023-01526.
    >> Share

  46. TANG Z, Li L, Huang X, Zhao Y, et al
    Association of molecular subtypes and treatment with survival in invasive micropapillary breast cancer: an analysis of the Surveillance, Epidemiology, and End Results database.
    Breast Cancer. 2023 Dec 3. doi: 10.1007/s12282-023-01523.
    >> Share

    November 2023
  47. IESATO A, Fushimi A, Tahara R, Terada M, et al
    A novel system to provide information via online YouTube videos and an evaluation of current online information about hereditary breast cancer.
    Breast Cancer. 2023 Nov 23. doi: 10.1007/s12282-023-01512.
    >> Share

  48. NISHIKAWA Y, Agatsuma N, Utsumi T, Funakoshi T, et al
    Medical care costs according to the stage and subtype of breast cancer in a municipal setting: a case study of Hachioji City, Japan.
    Breast Cancer. 2023 Nov 20. doi: 10.1007/s12282-023-01517.
    >> Share

  49. JING R, Bai S, Zhang P, Ren H, et al
    IDO-1 impairs antitumor immunity of natural killer cells in triple-negative breast cancer via up-regulation of HLA-G.
    Breast Cancer. 2023 Nov 19. doi: 10.1007/s12282-023-01522.
    >> Share

  50. FATHY A, Abdelrazek MA, Attallah AM, Abouzid A, et al
    Hepatitis C virus may accelerate breast cancer progression by increasing mutant p53 and c-Myc oncoproteins circulating levels.
    Breast Cancer. 2023 Nov 16. doi: 10.1007/s12282-023-01519.
    >> Share

  51. KUBOTA K, Nakashima K, Nakashima K, Kataoka M, et al
    The Japanese breast cancer society clinical practice guidelines for breast cancer screening and diagnosis, 2022 edition.
    Breast Cancer. 2023 Nov 16. doi: 10.1007/s12282-023-01521.
    >> Share

  52. PELZER F, Troger W, Reif M, Schonberg S, et al
    Fatigue and quality of life during neoadjuvant chemotherapy of early breast cancer: a prospective multicenter cohort study.
    Breast Cancer. 2023 Nov 15. doi: 10.1007/s12282-023-01520.
    >> Share

  53. PAPPOT H, Bjornsson BP, Krause O, Baeksted C, et al
    Machine learning applied in patient-reported outcome research-exploring symptoms in adjuvant treatment of breast cancer.
    Breast Cancer. 2023 Nov 8. doi: 10.1007/s12282-023-01515.
    >> Share

  54. HONMA N, Yoshida M, Kinowaki K, Horii R, et al
    The Japanese breast cancer society clinical practice guidelines for pathological diagnosis of breast cancer, 2022 edition.
    Breast Cancer. 2023 Nov 7. doi: 10.1007/s12282-023-01518.
    >> Share

  55. SHEN X, Wang G, He H, Shang P, et al
    SLC38A5 promotes glutamine metabolism and inhibits cisplatin chemosensitivity in breast cancer.
    Breast Cancer. 2023 Nov 2. doi: 10.1007/s12282-023-01516.
    >> Share

  56. WILLIAMSON M, Press DJ, Hansen SA, Tomar A, et al
    Population-level impact of adjuvant trastuzumab emtansine on the incidence of metastatic breast cancer: an epidemiological prediction model of women with HER2-positive early breast cancer and residual disease following neoadjuvant therapy.
    Breast Cancer. 2023 Nov 1. doi: 10.1007/s12282-023-01514.
    >> Share

  57. TERANAKA R, Fujimoto H, Masuda T, Kuroda M, et al
    Ex vivo dual gene therapy using human adipocytes secreting anti-HER2 antibody on HER2-positive xenograft tumor models.
    Breast Cancer. 2023;30:1018-1027.
    >> Share

  58. PAN J, Peng L, Tong X, Chen X, et al
    Prognosis of post-neoadjuvant therapy patients who underwent immediate breast reconstruction: a SEER-based, propensity-matched study.
    Breast Cancer. 2023;30:986-996.
    >> Share

  59. COLDITZ C, Keinki C, Huebner J
    Self-help management of patients undergoing chemotherapy: analysis of the online forum of the women's self-help association against cancer.
    Breast Cancer. 2023;30:926-932.
    >> Share

    October 2023
  60. TAKAHASHI M, Osako T, Yasojima H, Inoue K, et al
    Overall survival in Japanese patients with ER+/HER2- advanced breast cancer treated with first-line palbociclib plus letrozole.
    Breast Cancer. 2023 Oct 26. doi: 10.1007/s12282-023-01511.
    >> Share

  61. SAKAI T, Kutomi G, Shien T, Asaga S, et al
    The Japanese Breast Cancer Society Clinical Practice Guidelines for surgical treatment of breast cancer, 2022 edition.
    Breast Cancer. 2023 Oct 16. doi: 10.1007/s12282-023-01510.
    >> Share

  62. KONG L, Yang Z, Zheng C, Lu T, et al
    Psychometric evaluation of the Chinese version of the breast cancer perception scale for community women: a translation and validation study.
    Breast Cancer. 2023 Oct 13. doi: 10.1007/s12282-023-01508.
    >> Share

  63. UEMATSU T
    Rethinking screening mammography in Japan: next-generation breast cancer screening through breast awareness and supplemental ultrasonography.
    Breast Cancer. 2023 Oct 12. doi: 10.1007/s12282-023-01506.
    >> Share

  64. FUJIKI Y, Kashiwaba M, Sato M, Kawano J, et al
    Long-term prognostic value of the GenesWell BCT score in Asian women with hormone receptor-positive/HER2-negative early breast cancer.
    Breast Cancer. 2023 Oct 9. doi: 10.1007/s12282-023-01509.
    >> Share

  65. TERADA M, Ito A, Kikawa Y, Koizumi K, et al
    The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition.
    Breast Cancer. 2023 Oct 7. doi: 10.1007/s12282-023-01505.
    >> Share

  66. SUZUKI K, Ohe R, Kabasawa T, Kitaoka T, et al
    Histological spatial analysis on the induction of PD-L1(+) macrophages by CD8(+) T cells at the marginal microenvironment of triple-negative breast cancer.
    Breast Cancer. 2023 Oct 4. doi: 10.1007/s12282-023-01507.
    >> Share

  67. KUSAMA H, Kittaka N, Soma A, Taniguchi A, et al
    Predictive factors for response to neoadjuvant chemotherapy: inflammatory and immune markers in triple-negative breast cancer.
    Breast Cancer. 2023 Oct 2. doi: 10.1007/s12282-023-01504.
    >> Share

    September 2023
  68. PATIL PB, Patel JK
    Preparation, characterization, and in vitro cytotoxicity activity of allyl-isothiocyanate-embedded polymeric nanoparticles for potential breast cancer targeting.
    Breast Cancer. 2023 Sep 11. doi: 10.1007/s12282-023-01501.
    >> Share

  69. VIDULA N, Yau C, Rugo HS
    Glutaminase (GLS1) gene expression in primary breast cancer.
    Breast Cancer. 2023 Sep 7. doi: 10.1007/s12282-023-01502.
    >> Share

  70. VOLLBACH FH, Neuss C, Siegwart LC, Bigdeli AK, et al
    The transverse myocutaneous gracilis flap (TMG) for breast reconstruction: ipsi vs. contralateral harvest-aesthetic outcome and refinement procedures.
    Breast Cancer. 2023;30:845-855.
    >> Share

  71. GHILLI M, Mariniello MD, Ferre F, Morganti R, et al
    Quality of life and satisfaction of patients after oncoplastic or traditional breast-conserving surgery using the BREAST-Q (BCT module): a prospective study.
    Breast Cancer. 2023;30:802-809.
    >> Share

  72. TAKEHARA Y, Matsuda N, Kobayashi D, Yoshida A, et al
    Radiation-induced angiosarcoma of the breast: individual participant meta-analysis of Japanese population.
    Breast Cancer. 2023;30:739-747.
    >> Share

  73. FUKUI R, Watanabe T, Morimoto K, Fujimoto Y, et al
    An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers.
    Breast Cancer. 2023;30:703-713.
    >> Share

    August 2023
  74. DONG H, Yang C, Chen X, Sun H, et al
    Breast cancer-derived exosomal lncRNA SNHG14 induces normal fibroblast activation to cancer-associated fibroblasts via the EBF1/FAM171A1 axis.
    Breast Cancer. 2023 Aug 31. doi: 10.1007/s12282-023-01496.
    >> Share

  75. SANUKI F, Mikami Y, Nishimura H, Fujita Y, et al
    Immunohistological analysis of B7-H4, IDO1, and PD-L1 expression and tumor immune microenvironment based on triple-negative breast cancer subtypes.
    Breast Cancer. 2023 Aug 29. doi: 10.1007/s12282-023-01498.
    >> Share

  76. MURATA T, Yoshida M, Shiino S, Watase C, et al
    Assessment of nuclear grade-based recurrence risk classification in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive high-risk early breast cancer.
    Breast Cancer. 2023 Aug 23. doi: 10.1007/s12282-023-01500.
    >> Share

  77. OHSUMI S
    Reply to "Is venous thromboembolism a time-dependent event in breast cancer patients taking tamoxifen?".
    Breast Cancer. 2023 Aug 21. doi: 10.1007/s12282-023-01495.
    >> Share

  78. OEI SL, Thronicke A, Grieb G, Schad F, et al
    Evaluation of quality of life in breast cancer patients who underwent breast-conserving surgery or mastectomy using real-world data.
    Breast Cancer. 2023 Aug 16. doi: 10.1007/s12282-023-01494.
    >> Share

  79. JHANGIANI N, Philip M, Jatoi I
    Breast cancer screening guidelines: discrepancies raise concerns about validity.
    Breast Cancer. 2023 Aug 14. doi: 10.1007/s12282-023-01493.
    >> Share

  80. AKSHAYA RL, Saranya I, Selvamurugan N
    MicroRNAs mediated interaction of tumor microenvironment cells with breast cancer cells during bone metastasis.
    Breast Cancer. 2023 Aug 14. doi: 10.1007/s12282-023-01491.
    >> Share

  81. ILIE SM, Briot N, Constantin G, Roussot N, et al
    Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.
    Breast Cancer. 2023 Aug 10. doi: 10.1007/s12282-023-01490.
    >> Share

    July 2023
  82. CHEN ST, Lai HW, Chang JH, Liao CY, et al
    Diagnostic accuracy of pre-operative breast magnetic resonance imaging (MRI) in predicting axillary lymph node metastasis: variations in intrinsic subtypes, and strategy to improve negative predictive value-an analysis of 2473 invasive breast cancer p
    Breast Cancer. 2023 Jul 27. doi: 10.1007/s12282-023-01488.
    >> Share

  83. KAWAMURA C, Iwagami M, Sun Y, Komiyama J, et al
    Factors associated with non-participation in breast cancer screening: analysis of the 2016 and 2019 comprehensive survey of living conditions in Japan.
    Breast Cancer. 2023 Jul 25. doi: 10.1007/s12282-023-01486.
    >> Share

  84. FUTAMURA M, Nakayama T, Yoshinami T, Oshiro C, et al
    Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316).
    Breast Cancer. 2023 Jul 24. doi: 10.1007/s12282-023-01485.
    >> Share

  85. JESUS OJ, Luis CP, Matilde MF
    Effects of exercise on cancer-related cognitive impairment in breast cancer survivors: a scoping review.
    Breast Cancer. 2023 Jul 22. doi: 10.1007/s12282-023-01484.
    >> Share

  86. LI C, Yuan Q, Deng T, Xu G, et al
    Prognosis difference between HER2-low and HER2-zero breast cancer patients: a systematic review and meta-analysis.
    Breast Cancer. 2023 Jul 20. doi: 10.1007/s12282-023-01487.
    >> Share

  87. JIANG T, Chen J, Wang Z, Wang X, et al
    miR-4796 enhances the sensitivity of breast cancer cells to ionising radiation by impairing the DNA repair pathway.
    Breast Cancer. 2023 Jul 17. doi: 10.1007/s12282-023-01482.
    >> Share

  88. MORIKAWA H, Oba T, Kiyosawa N, Iji R, et al
    Significance of skeletal muscle index-to-body mass index ratio as a predictor of post-surgical bleeding after mastectomy in patients with breast cancer.
    Breast Cancer. 2023 Jul 13. doi: 10.1007/s12282-023-01483.
    >> Share

  89. SUZUKI Y, Iwamoto T, Uno M, Hatono M, et al
    Development and validation of a symptom illustration scale from the patient-reported outcome common terminology criteria for adverse events for patients with breast cancer.
    Breast Cancer. 2023 Jul 8. doi: 10.1007/s12282-023-01480.
    >> Share

  90. SAEKI S, Iwatani T, Kitano A, Sakurai N, et al
    Correction: Factors associated with financial toxicity in patients with breast cancer in Japan: a comparison of patient and physician perspectives.
    Breast Cancer. 2023 Jul 3. doi: 10.1007/s12282-023-01479.
    >> Share

  91. LI L, Yang W, Jia D, Zheng S, et al
    Establishment of a N1-methyladenosine-related risk signature for breast carcinoma by bioinformatics analysis and experimental validation.
    Breast Cancer. 2023;30:666-684.
    >> Share

  92. WATANABE J, Kataoka Y, Koike A, Miki A, et al
    Efficacy and safety of surgical energy devices for axillary node dissection: a systematic review and network meta-analysis.
    Breast Cancer. 2023;30:531-540.
    >> Share

  93. KAWAGUCHI S, Kinowaki K, Tamura N, Masumoto T, et al
    High-accuracy prediction of axillary lymph node metastasis in invasive lobular carcinoma using focal cortical thickening on magnetic resonance imaging.
    Breast Cancer. 2023;30:637-646.
    >> Share

  94. MARINIELLO MD, Ghilli M, Favati B, Gerges I, et al
    Cell-free biomimetic polyurethane-based scaffold for breast reconstruction following non-malignant lesion resection. A first-in-human study.
    Breast Cancer. 2023;30:559-569.
    >> Share

  95. OIWA M, Suda N, Morita T, Takahashi Y, et al
    Validity of computed mean compressed fibroglandular tissue thickness and breast composition for stratification of masking risk in Japanese women.
    Breast Cancer. 2023;30:541-551.
    >> Share

  96. KIKUCHI M, Gomi N, Ueki A, Osako T, et al
    Effectiveness and tasks of breast MRI surveillance for high-risk women with cancer susceptibility genes other than BRCA1/2: a single institution study.
    Breast Cancer. 2023;30:577-583.
    >> Share

  97. FERNANDO H, Noelia G, Maria E, Pedro M, et al
    Centrally located breast carcinomas treated with central quadrantectomy and immediate nipple-areola reconstruction: a cohort study.
    Breast Cancer. 2023;30:552-558.
    >> Share

    June 2023
  98. KUTHETHUR R, Jerome MS, Subbannayya Y, Chakrabarty S, et al
    An integrated analysis of microRNAs regulating DNA damage response in triple-negative breast cancer.
    Breast Cancer. 2023 Jun 21. doi: 10.1007/s12282-023-01477.
    >> Share

  99. YIN M, Gu K, Cai H, Shu XO, et al
    Association between chronic pain and quality of life in long-term breast cancer survivors: a prospective analysis.
    Breast Cancer. 2023 Jun 17. doi: 10.1007/s12282-023-01472.
    >> Share

  100. RAINONE M, Behrendt CE, Kasparian S, Nguyen T, et al
    HER2-targeted antibody-drug conjugates for breast cancer: ancestry and dose adjustment for thrombocytopenia.
    Breast Cancer. 2023 Jun 16. doi: 10.1007/s12282-023-01473.
    >> Share

  101. SAEKI S, Iwatani T, Kitano A, Sakurai N, et al
    Factors associated with financial toxicity in patients with breast cancer in Japan: a comparison of patient and physician perspectives.
    Breast Cancer. 2023 Jun 13. doi: 10.1007/s12282-023-01476.
    >> Share

  102. YUSOF KM, Mohd Sidik S, Mahmud R, Abdullah M, et al
    Association of psychological distress with arm morbidity symptoms in breast cancer survivors: outcomes from the use of PHQ-9 and GAD-7 questionnaires.
    Breast Cancer. 2023 Jun 12. doi: 10.1007/s12282-023-01475.
    >> Share

  103. VAN BEKKUM S, Clarijs ME, van der Veen FJC, van Rosmalen J, et al
    What affects women's decision-making on breast reconstruction after mastectomy for breast cancer?
    Breast Cancer. 2023 Jun 12. doi: 10.1007/s12282-023-01471.
    >> Share

    May 2023
  104. ABDOLLAHI E, Mozdarani H, Alizadeh BZ
    Role of circ-FOXO3 and miR-23a in radiosensitivity of breast cancer.
    Breast Cancer. 2023 May 24. doi: 10.1007/s12282-023-01463.
    >> Share

  105. NOZAWA K, Terada M, Onishi M, Ozaki Y, et al
    Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR + , HER2- metastatic breast cancer patients in Japan.
    Breast Cancer. 2023 May 22. doi: 10.1007/s12282-023-01461.
    >> Share

  106. LIN L, Pfender K, Ditsch N, Kuhn C, et al
    KLF11 is an independent negative prognostic factor for breast cancer from a cohort study and induces proliferation and inhibits apoptosis in vitro.
    Breast Cancer. 2023 May 18. doi: 10.1007/s12282-023-01470.
    >> Share

  107. KHALID F, Takagi K, Sato A, Yamaguchi M, et al
    Interleukin (IL)-17A in triple-negative breast cancer: a potent prognostic factor associated with intratumoral neutrophil infiltration.
    Breast Cancer. 2023 May 13. doi: 10.1007/s12282-023-01467.
    >> Share

  108. YAMAUCHI H, Toi M, Takayama S, Nakamura S, et al
    Correction: Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial.
    Breast Cancer. 2023 May 12. doi: 10.1007/s12282-023-01468.
    >> Share

  109. SAKAMOTO T, Tanimoto K, Eguchi H, Sasaki S, et al
    Resveratrol exhibits diverse anti-cancer activities through epigenetic regulation of E-cadherin and p21 in triple-negative breast cancer cells.
    Breast Cancer. 2023 May 11. doi: 10.1007/s12282-023-01465.
    >> Share

  110. ALTUNDAG K
    Is there any association between acute kidney injury and olaparib use in patients with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial.
    Breast Cancer. 2023 May 11. doi: 10.1007/s12282-023-01469.
    >> Share

  111. ALTUNDAG K
    Is venous thromboembolism a time-dependent event in breast cancer patients taking tamoxifen?
    Breast Cancer. 2023 May 4. doi: 10.1007/s12282-023-01464.
    >> Share

  112. PATHAK R, Leslie M, Dondapati P, Davis R, et al
    Increased breast cancer mortality due to treatment delay and needle biopsy type: a retrospective analysis of SEER-medicare.
    Breast Cancer. 2023 May 3. doi: 10.1007/s12282-023-01456.
    >> Share

  113. LI JJ, Yu Y, Ge J
    HER2-low-positive and response to NACT and prognosis in HER2-negative non-metastatic BC.
    Breast Cancer. 2023;30:364-378.
    >> Share

    April 2023
  114. TOMIOKA N, Hatanaka KC, Okuyama D, Watanabe KI, et al
    Correction: Programmed death ligand 1-positive immune cells in primary tumor or metastatic axillary lymph nodes can predict prognosis of triple-negative breast cancer even when present at < 1% in the tumor region.
    Breast Cancer. 2023 Apr 27. doi: 10.1007/s12282-023-01454.
    >> Share

  115. JIAO Y, Guo X, Lv Q
    Options of locoregional therapy for primary foci of breast cancer influence the rate of nonregional lymph node metastasis in N2-N3 status patients: a SEER database analysis.
    Breast Cancer. 2023 Apr 27. doi: 10.1007/s12282-023-01459.
    >> Share

  116. OHSUMI S, Watanabe K, Kondo N, Kosaka Y, et al
    Venous thromboembolism in Japanese patients with breast cancer: subgroup analysis of the Cancer-VTE Registry.
    Breast Cancer. 2023 Apr 17. doi: 10.1007/s12282-023-01452.
    >> Share

  117. NOMURA T, Kawai M, Fukuma Y, Koike Y, et al
    Alcohol consumption and breast cancer prognosis after breast cancer diagnosis: a systematic review and meta‑analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2022 edition.
    Breast Cancer. 2023 Apr 8. doi: 10.1007/s12282-023-01455.
    >> Share

  118. YAMAUCHI H, Toi M, Takayama S, Nakamura S, et al
    Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial.
    Breast Cancer. 2023 Apr 1. doi: 10.1007/s12282-023-01451.
    >> Share

    March 2023
  119. TAMURA K, Mukohara T, Yonemori K, Kawabata Y, et al
    Phase 1 study of oral selective estrogen receptor degrader (SERD) amcenestrant (SAR439859), in Japanese women with ER-positive and HER2-negative advanced breast cancer (AMEERA-2).
    Breast Cancer. 2023 Mar 29. doi: 10.1007/s12282-023-01443.
    >> Share

  120. AKYOL M, Tugral A, Aribas Z, Bakar Y, et al
    Assessment of the cardiorespiratory fitness and the quality of life of patients with breast cancer undergoing chemotherapy: a prospective study.
    Breast Cancer. 2023 Mar 23. doi: 10.1007/s12282-023-01453.
    >> Share

  121. SOWA Y, Inafuku N, Tsuge I, Yamanaka H, et al
    Development and implementation of a decision aid for post-mastectomy breast reconstruction for Japanese women with breast cancer: a field-testing study.
    Breast Cancer. 2023 Mar 18. doi: 10.1007/s12282-023-01447.
    >> Share

  122. NAGAHASHI M, Ling Y, Toshikawa C, Hayashida T, et al
    Copy number alteration is an independent prognostic biomarker in triple-negative breast cancer patients.
    Breast Cancer. 2023 Mar 17. doi: 10.1007/s12282-023-01449.
    >> Share

  123. JINBO K, Fujita T, Kasahara R, Jinbo R, et al
    The effect of combined risk factors on breast cancer-related lymphedema: a study using decision trees.
    Breast Cancer. 2023 Mar 14. doi: 10.1007/s12282-023-01450.
    >> Share

  124. TOMIOKA N, Hatanaka KC, Okuyama D, Watanabe KI, et al
    Programmed death ligand 1-positive immune cells in primary tumor or metastatic axillary lymph nodes can predict prognosis of triple-negative breast cancer even when present at < 1% in the tumor region.
    Breast Cancer. 2023 Mar 9. doi: 10.1007/s12282-023-01442.
    >> Share

  125. SONG C, Kendi AT, Shim JY, Jung D, et al
    ER-/PR+ breast cancer is controlled more effectively with an inflammatory inhibitor than hormonal inhibitor.
    Breast Cancer. 2023 Mar 1. doi: 10.1007/s12282-023-01437.
    >> Share

  126. WANG F, Fang L, Fu B, Fan C, et al
    Construction of a prognostic risk assessment model for HER2 + breast cancer based on autophagy-related genes.
    Breast Cancer. 2023 Mar 1. doi: 10.1007/s12282-023-01440.
    >> Share

  127. YAMAKADO R, Ishitobi M, Kondo N, Yamauchi C, et al
    Physicians' perception about the impact of breast reconstruction on patient prognosis: a survey in Japan.
    Breast Cancer. 2023;30:302-308.
    >> Share

  128. KWON MR, Chang Y, Park B, Ryu S, et al
    Performance analysis of screening mammography in Asian women under 40 years.
    Breast Cancer. 2023;30:241-248.
    >> Share

  129. KONARA MUDIYANSELAGE SP, Wu YL, Kukreti S, Chen CC, et al
    Dynamic changes in quality of life, psychological status, and body image in women who underwent a mastectomy as compared with breast reconstruction: an 8-year follow up.
    Breast Cancer. 2023;30:226-240.
    >> Share

    February 2023
  130. ZHANG H, Barner JC, Moczygemba LR, Rascati KL, et al
    Comparing survival outcomes between neoadjuvant and adjuvant chemotherapy within breast cancer subtypes and stages among older women: a SEER-Medicare analysis.
    Breast Cancer. 2023 Feb 26. doi: 10.1007/s12282-023-01441.
    >> Share

  131. KOU K, Cameron J, Youl P, Pyke C, et al
    Severity and risk factors of interval breast cancer in Queensland, Australia: a population-based study.
    Breast Cancer. 2023 Feb 21. doi: 10.1007/s12282-023-01439.
    >> Share

  132. JIANG F, Yang L, Jiao X
    Dynamic network biomarker to determine the critical point of breast cancer stage progression.
    Breast Cancer. 2023 Feb 18. doi: 10.1007/s12282-023-01438.
    >> Share

  133. QING X, Yuan C, Wang K
    Characterization of protein-based risk signature to predict prognosis and evaluate the tumor immune environment in breast cancer.
    Breast Cancer. 2023 Feb 2. doi: 10.1007/s12282-023-01435.
    >> Share

    January 2023
  134. KADA MOHAMMED S, Billa O, Ladoire S, Jankowski C, et al
    HER2-positive invasive lobular carcinoma: a rare breast cancer which may not necessarily require anti-HER2 therapy. A population-based study.
    Breast Cancer. 2023 Jan 30. doi: 10.1007/s12282-022-01432.
    >> Share

  135. IMOTO S, Wang K, Bi XW, Liu G, et al
    Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1).
    Breast Cancer. 2023 Jan 23. doi: 10.1007/s12282-023-01436.
    >> Share

  136. LI Y, Na F, Pei J
    Construction and characterization of a cuproptosis- and immune checkpoint-based LncRNAs signature for breast cancer risk stratification.
    Breast Cancer. 2023 Jan 20. doi: 10.1007/s12282-023-01434.
    >> Share

  137. COLLET L, Eberst L, Ludovic G, Debled M, et al
    Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohort.
    Breast Cancer. 2023 Jan 11. doi: 10.1007/s12282-022-01427.
    >> Share

  138. HASAN MT, Hamouda M, Khashab MKE, Elsnhory AB, et al
    Oncoplastic versus conventional breast-conserving surgery in breast cancer: a pooled analysis of 6941 female patients.
    Breast Cancer. 2023 Jan 9. doi: 10.1007/s12282-022-01430.
    >> Share

  139. MA J, Wang F, Chen C, Ji J, et al
    Identification of prognostic genes signature and construction of ceRNA network in pirarubicin treatment of triple-negative breast cancer.
    Breast Cancer. 2023 Jan 9. doi: 10.1007/s12282-023-01433.
    >> Share

  140. FUTAMURA M, Ishihara K, Nagao Y, Ogiso A, et al
    Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04).
    Breast Cancer. 2023 Jan 7. doi: 10.1007/s12282-022-01425.
    >> Share

  141. BAILLEUX C, Arnaud A, Frenel JS, Chabaud S, et al
    CHEOPS trial: a GINECO group randomized phase II assessing addition of a non-steroidal aromatase inhibitor to oral vinorelbine in pre-treated metastatic breast cancer patients.
    Breast Cancer. 2023 Jan 5. doi: 10.1007/s12282-022-01426.
    >> Share

  142. OCHI T, Yoshida A, Takahashi O, Kajiura Y, et al
    Prognostic effect of subsequent childbirth after the diagnosis of breast cancer using propensity score matching analysis.
    Breast Cancer. 2023 Jan 3. doi: 10.1007/s12282-022-01429.
    >> Share

  143. OHSUMI S, Nishimura R, Masuda N, Akashi-Tanaka S, et al
    A prospective analysis of two studies that used the 5-mm interval slices and 5-mm margin-free method for ipsilateral breast tumor recurrence after breast-conserving surgery without radiotherapy.
    Breast Cancer. 2023;30:131-138.
    >> Share

  144. OHNEDA K, Hamanaka Y, Kawame H, Fuse N, et al
    Returning individual genomic results to population-based cohort study participants with BRCA1/2 pathogenic variants.
    Breast Cancer. 2023;30:110-120.
    >> Share

  145. UEMATSU T, Nakashima K, Harada TL, Nasu H, et al
    Artificial intelligence computer-aided detection enhances synthesized mammograms: comparison with original digital mammograms alone and in combination with tomosynthesis images in an experimental setting.
    Breast Cancer. 2023;30:46-55.
    >> Share

    December 2022
  146. ANUSZKIEWICZ K, Jankau J, Kur M
    What do we know about treating breast-cancer-related lymphedema? Review of the current knowledge about therapeutic options.
    Breast Cancer. 2022 Dec 26. doi: 10.1007/s12282-022-01428.
    >> Share

  147. TAJI T, Odan N, Kataoka Y, Ikeda M, et al
    Promoters of BRCA testing under insurance coverage for non-metastatic breast cancer patients in Japan: a retrospective cohort study.
    Breast Cancer. 2022 Dec 22. doi: 10.1007/s12282-022-01424.
    >> Share

  148. TADA K, Kumamaru H, Miyata H, Asaga S, et al
    Characteristics of female breast cancer in japan: annual report of the National Clinical Database in 2018.
    Breast Cancer. 2022 Dec 22. doi: 10.1007/s12282-022-01423.
    >> Share

  149. MANFUKU M, Nishigami T, Mibu A, Yamashita H, et al
    Predictors of persistent post-surgical pain intensity and interference at 1 year after breast cancer surgery: assessing central sensitization, central sensitivity symptoms, and psychological factors.
    Breast Cancer. 2022 Dec 18. doi: 10.1007/s12282-022-01420.
    >> Share

  150. KAWAMOTO T, Shikama N, Imano N, Kubota H, et al
    Incidence of and risk factors for non-hematologic toxicity with combined radiotherapy and CDK4/6 inhibitors in metastatic breast cancer using dose-volume parameters analysis: a multicenter cohort study.
    Breast Cancer. 2022 Dec 17. doi: 10.1007/s12282-022-01422.
    >> Share

  151. CHU J, Min KW, Kim DH, Son BK, et al
    High PPFIA1 expression promotes cancer survival by suppressing CD8+ T cells in breast cancer: drug discovery and machine learning approach.
    Breast Cancer. 2022 Dec 7. doi: 10.1007/s12282-022-01419.
    >> Share

  152. WATZEK JT, Gordon LG, Sandler CX, Spence RR, et al
    A cost-consequences analysis of the SAFE trial: a comparative, effectiveness trial evaluating high- versus low-supervision of an exercise intervention for women with breast cancer.
    Breast Cancer. 2022 Dec 3. doi: 10.1007/s12282-022-01418.
    >> Share

    November 2022
  153. NGUYEN HM, Paulishak W, Oladejo M, Wood L, et al
    Dynamic tumor microenvironment, molecular heterogeneity, and distinct immunologic portrait of triple-negative breast cancer: an impact on classification and treatment approaches.
    Breast Cancer. 2022 Nov 18. pii: 10.1007/s12282-022-01415.
    >> Share

  154. SEKIGUCHI K, Sumi M, Saito A, Zenda S, et al
    Correction to: The effectiveness of moisturizer on acute radiation-induced dermatitis in breast cancer patients: a systematic review and meta-analysis.
    Breast Cancer. 2022 Nov 17. pii: 10.1007/s12282-022-01416.
    >> Share

  155. NOGUCHI M, Inokuchi M, Yokoi-Noguchi M, Morioka E, et al
    Conservative axillary surgery is emerging in the surgical management of breast cancer.
    Breast Cancer. 2022 Nov 7. pii: 10.1007/s12282-022-01409.
    >> Share

  156. SHIRAISHI M, Sowa Y, Tsuge I, Shiraishi A, et al
    Risk factors associated with chronic pain after mastectomy: a prospective study with a 5-year follow-up in Japan.
    Breast Cancer. 2022;29:1133-1139.
    >> Share

  157. KARAKAWA R, Konishi T, Yoshimatsu H, Fuse Y, et al
    Comparison of short-term outcomes between pedicled- and free-flap autologous breast reconstruction: a nationwide inpatient database study in Japan.
    Breast Cancer. 2022;29:1067-1075.
    >> Share

  158. ALAM B, Akbari AR, Alali B, Thankan E, et al
    Antibiotic prophylaxis in breast surgery: a meta-analysis to identify the optimal strategy to reduce infection rates in breast surgery.
    Breast Cancer. 2022;29:945-956.
    >> Share

  159. MUSTAFA ALI MK, Samhouri Y, Law JY, Khan C, et al
    Patterns of treatment and their outcomes in primary breast lymphoma; a comprehensive population-based analysis.
    Breast Cancer. 2022;29:1022-1031.
    >> Share

  160. HASHIMOTO R, Akashi-Tanaka S, Watanabe C, Masuda H, et al
    Diagnostic performance of dedicated breast positron emission tomography.
    Breast Cancer. 2022;29:1013-1021.
    >> Share

  161. BAILEY S, Ezratty C, Mhango G, Lin JJ, et al
    Clinical and sociodemographic risk factors associated with the development of second primary cancers among postmenopausal breast cancer survivors.
    Breast Cancer. 2022 Nov 1. pii: 10.1007/s12282-022-01411.
    >> Share

    October 2022
  162. SUZUKI K, Sasada S, Nishi H, Kimura Y, et al
    Impact of oral hygiene on febrile neutropenia during breast cancer chemotherapy.
    Breast Cancer. 2022 Oct 21. pii: 10.1007/s12282-022-01410.
    >> Share

  163. SEKIGUCHI K, Sumi M, Saito A, Zenda S, et al
    The effectiveness of moisturizer on acute radiation-induced dermatitis in breast cancer patients: a systematic review and meta-analysis.
    Breast Cancer. 2022 Oct 18. pii: 10.1007/s12282-022-01403.
    >> Share

  164. MAVROPALIAS G, Cormie P, Peddle-McIntyre CJ, Galvao DA, et al
    The effects of home-based exercise therapy for breast cancer-related fatigue induced by radical radiotherapy.
    Breast Cancer. 2022 Oct 14. pii: 10.1007/s12282-022-01408.
    >> Share

    September 2022
  165. COLOMBAGE UN, Soh SE, Lin KY, Kruger J, et al
    The feasibility of pelvic floor training to treat urinary incontinence in women with breast cancer: a telehealth intervention trial.
    Breast Cancer. 2022 Sep 26. pii: 10.1007/s12282-022-01405.
    >> Share

  166. LIAO N, Li C, Cao L, Chen Y, et al
    Single-cell profile of tumor and immune cells in primary breast cancer, sentinel lymph node, and metastatic lymph node.
    Breast Cancer. 2022 Sep 21. pii: 10.1007/s12282-022-01400.
    >> Share

  167. YANG ZY, Yin SP, Ren Q, Lu DW, et al
    Correction to: BAHD1 serves as a critical regulator of breast cancer cell proliferation and invasion.
    Breast Cancer. 2022 Sep 16. pii: 10.1007/s12282-022-01402.
    >> Share

  168. MANSFIELD C, Botha W, Vondeling GT, Klein K, et al
    Patient preferences for features of HER2-targeted treatment of advanced or metastatic breast cancer: a discrete-choice experiment study.
    Breast Cancer. 2022 Sep 8. pii: 10.1007/s12282-022-01394.
    >> Share

  169. ALEIXO GFP, Valente SA, Wei W, Chen PH, et al
    Sarcopenia detected with bioelectrical impedance versus CT scan and chemotherapy tolerance in patients with early breast cancer.
    Breast Cancer. 2022 Sep 5. pii: 10.1007/s12282-022-01401.
    >> Share

  170. YAMAMOTO Y, Yamashiro H, Schneeweiss A, Muller V, et al
    Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational stu
    Breast Cancer. 2022 Sep 3. pii: 10.1007/s12282-022-01399.
    >> Share

  171. JUNG J, Hwang KT, Choi IS, Kim BH, et al
    Racial differences in predictive value of the 21-gene recurrence score assay: a population-based study using the SEER database.
    Breast Cancer. 2022;29:889-898.
    >> Share

  172. UEMATSU T
    Sensitivity and specificity of screening mammography without clinical breast examination among Japanese women aged 40-49 years: analysis of data from the J-START results.
    Breast Cancer. 2022;29:928-931.
    >> Share

  173. WOO JW, Choi HY, Kim M, Chung YR, et al
    miR-145, miR-205 and miR-451: potential tumor suppressors involved in the progression of in situ to invasive carcinoma of the breast.
    Breast Cancer. 2022;29:814-824.
    >> Share

    August 2022
  174. NGAN TT, Browne S, Goodwin M, Van Minh H, et al
    Cost-effectiveness of clinical breast examination screening programme among HER2-positive breast cancer patients: a modelling study.
    Breast Cancer. 2022 Aug 26. pii: 10.1007/s12282-022-01398.
    >> Share

  175. CINAR V, Hamurcu Z, Guler A, Nurdinov N, et al
    Serotonin 5-HT7 receptor is a biomarker poor prognostic factor and induces proliferation of triple-negative breast cancer cells through FOXM1.
    Breast Cancer. 2022 Aug 25. pii: 10.1007/s12282-022-01391.
    >> Share

  176. KONISHI T, Tanabe M, Michihata N, Matsui H, et al
    Risk factors for arm lymphedema following breast cancer surgery: a Japanese nationwide database study of 84,022 patients.
    Breast Cancer. 2022 Aug 23. pii: 10.1007/s12282-022-01395.
    >> Share

  177. ZHU Y, Iwamoto T, Kajiwara Y, Takahashi Y, et al
    Predictive value of immune genomic signatures from breast cancer cohorts containing data for both response to neoadjuvant chemotherapy and prognosis after surgery.
    Breast Cancer. 2022 Aug 22. pii: 10.1007/s12282-022-01397.
    >> Share

  178. HAJI GHAFFARI M, Simonian M, Salimi A, Mirzadegan E, et al
    A novel ADC targeting cell surface fibromodulin in a mouse model of triple-negative breast cancer.
    Breast Cancer. 2022 Aug 18. pii: 10.1007/s12282-022-01393.
    >> Share

    July 2022
  179. KOTANI H, Masuda N, Yamashita T, Naito Y, et al
    Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study.
    Breast Cancer. 2022 Jul 30. pii: 10.1007/s12282-022-01390.
    >> Share

  180. ZHU J, Wu W, Togashi Y, Taira Nihira N, et al
    Alteration of Trop-2 expression in breast cancer cells by clinically used therapeutic agents and acquired tamoxifen resistance.
    Breast Cancer. 2022 Jul 27. pii: 10.1007/s12282-022-01389.
    >> Share

  181. MOTALEBZADEH J, Eskandari E
    Comprehensive analysis of DRAIC and TP53TG1 in breast cancer luminal subtypes through the construction of lncRNAs regulatory model.
    Breast Cancer. 2022 Jul 24. pii: 10.1007/s12282-022-01385.
    >> Share

  182. NOZAKI M, Kagami Y, Takahashi M, Machida R, et al
    Evaluation of breast cosmetic changes with a computer-software; the breast cancer conservative treatment cosmetic results (BCCT. core) in hypofractionated whole breast irradiation after breast-conserving surgery-supplementary analysis of multicenter s
    Breast Cancer. 2022 Jul 21. pii: 10.1007/s12282-022-01384.
    >> Share

  183. WOOD KC, Hidde M, Kendig T, Pergolotti M, et al
    Community-based outpatient rehabilitation for the treatment of breast cancer-related upper extremity disability: an evaluation of practice-based evidence.
    Breast Cancer. 2022 Jul 21. pii: 10.1007/s12282-022-01388.
    >> Share

  184. NAMBA T, Matsuda N, Rahman M, Kanomata N, et al
    Association between mammographic breast composition and breast cancer risk among Japanese women: a retrospective cohort study.
    Breast Cancer. 2022 Jul 13. pii: 10.1007/s12282-022-01376.
    >> Share

  185. NOURI-MAJD S, Salari-Moghaddam A, Benisi-Kohansal S, Azadbakht L, et al
    Dietary intake of branched-chain amino acids in relation to the risk of breast cancer.
    Breast Cancer. 2022 Jul 6. pii: 10.1007/s12282-022-01379.
    >> Share

  186. HAN R, Yang H, Ling C, Lu L, et al
    Neurospora crassa is a potential source of anti-cancer agents against breast cancer.
    Breast Cancer. 2022 Jul 5. pii: 10.1007/s12282-022-01383.
    >> Share

  187. TSUDA H, Kurosumi M, Akiyama F, Ohno S, et al
    Validation of a nuclear grading system for resected stage I-IIIA, high-risk, node-negative invasive breast carcinoma in the N.SAS-BC 01 trial.
    Breast Cancer. 2022;29:720-729.
    >> Share

  188. YOSHIDA K, Nose T, Otani Y, Asahi S, et al
    A Japanese prospective multi-institutional feasibility study on accelerated partial breast irradiation using multicatheter interstitial brachytherapy: clinical results with a median follow-up of 60 months.
    Breast Cancer. 2022;29:636-644.
    >> Share

  189. NAKAYAMA S, Masuda H, Miura S, Kuwayama T, et al
    Identifying ductal carcinoma in situ cases not requiring surgery to exclude postoperative upgrade to invasive ductal carcinoma.
    Breast Cancer. 2022;29:610-617.
    >> Share

  190. HAYASHI S, Kubo M, Kaneshiro K, Kai M, et al
    Genetic medicine is accelerating in Japan.
    Breast Cancer. 2022;29:659-665.
    >> Share

  191. GANDOMKAR Z, Lewis SJ, Li T, Ekpo EU, et al
    A machine learning model based on readers' characteristics to predict their performances in reading screening mammograms.
    Breast Cancer. 2022;29:589-598.
    >> Share

    June 2022
  192. DANG LA, Chazard E, Poncelet E, Serb T, et al
    Impact of artificial intelligence in breast cancer screening with mammography.
    Breast Cancer. 2022 Jun 28. pii: 10.1007/s12282-022-01375.
    >> Share

  193. WAGONER CW, Lee JT, Hanson ED, Kerr ZY, et al
    Impact of community-based exercise on fatigue in early breast cancer survivors: identifying potential determinants of change.
    Breast Cancer. 2022 Jun 24. pii: 10.1007/s12282-022-01380.
    >> Share

  194. WANG W, Qiu P, Li J
    Internal mammary lymph node metastasis in breast cancer patients based on anatomical imaging and functional imaging.
    Breast Cancer. 2022 Jun 24. pii: 10.1007/s12282-022-01377.
    >> Share

  195. SHIMOMURA A, Nagahashi M, Kumamaru H, Aogi K, et al
    Clinicopathological features of male patients with breast cancer based on a nationwide registry database in Japan.
    Breast Cancer. 2022 Jun 22. pii: 10.1007/s12282-022-01378.
    >> Share

  196. CHEN M, Chen W, Liu D, Chen W, et al
    Prognostic values of clinical and molecular features in HER2 low-breast cancer with hormonal receptor overexpression: features of HER2-low breast cancer.
    Breast Cancer. 2022 Jun 21. pii: 10.1007/s12282-022-01364.
    >> Share

  197. ZHANG X, Zhao X, Chang L, Liu F, et al
    LncRNA FOXD3-AS1 promotes breast cancer progression by mediating ARF6.
    Breast Cancer. 2022 Jun 9. pii: 10.1007/s12282-022-01373.
    >> Share

  198. LI Q, Lesseur C, Neugut AI, Santella RM, et al
    The associations of healthy lifestyle index with breast cancer incidence and mortality in a population-based study.
    Breast Cancer. 2022 Jun 3. pii: 10.1007/s12282-022-01374.
    >> Share

  199. VAZEH H, Behboudi E, Hashemzadeh-Omran A, Moradi A, et al
    Live-attenuated poliovirus-induced extrinsic apoptosis through Caspase 8 within breast cancer cell lines expressing CD155.
    Breast Cancer. 2022 Jun 1. pii: 10.1007/s12282-022-01372.
    >> Share

    May 2022
  200. MINOURA Y, Takahashi M, Maeda H, Kuwahara S, et al
    Significance of prostate/pancreatic/skin cancer family history for detecting BRCA2 pathogenic variant careers among patients with breast cancer.
    Breast Cancer. 2022 May 31. pii: 10.1007/s12282-022-01360.
    >> Share

  201. KATAOKA A, Ueno T, Yamauchi H, Uehiro N, et al
    Characteristics, treatment trends, and long-term outcomes of Japanese patients with pregnancy-associated breast cancer (PABC).
    Breast Cancer. 2022 May 23. pii: 10.1007/s12282-022-01362.
    >> Share

  202. LIN SQ, Su CM, Wu HC, Chou YY, et al
    Effect of patient decision aids on decisional conflict and regret associated with breast cancer surgery: a randomized controlled trial.
    Breast Cancer. 2022 May 19. pii: 10.1007/s12282-022-01370.
    >> Share

  203. BAN K, Tsunoda H, Togashi S, Kawakami M, et al
    Comparative study of the usefulness of adjunctive tomosynthesis in breast cancer screening by mammography and ultrasound in Japan.
    Breast Cancer. 2022 May 18. pii: 10.1007/s12282-022-01358.
    >> Share

  204. KHODABANDEH Z, Valilo M, Velaei K, Pirpour Tazehkand A, et al
    The potential role of nicotine in breast cancer initiation, development, angiogenesis, invasion, metastasis, and resistance to therapy.
    Breast Cancer. 2022 May 18. pii: 10.1007/s12282-022-01369.
    >> Share

  205. PANG Y, Wei Y, Kartsonaki C
    Associations of adiposity and weight change with recurrence and survival in breast cancer patients: a systematic review and meta-analysis.
    Breast Cancer. 2022 May 17. pii: 10.1007/s12282-022-01355.
    >> Share

  206. ROY P, Sur S, Das S, Wui WT, et al
    Phytochemical-conjugated bio-safe gold nanoparticles in breast cancer: a comprehensive update.
    Breast Cancer. 2022 May 16. pii: 10.1007/s12282-022-01368.
    >> Share

  207. PARK JK, Seo J, Yang EJ, Kang Y, et al
    Association of lymphatic flow velocity with surgical outcomes in patients undergoing lymphovenous anastomosis for breast cancer-related lymphedema.
    Breast Cancer. 2022 May 12. pii: 10.1007/s12282-022-01363.
    >> Share

  208. LI X, Wang Y, Zhang Y, Liu B, et al
    Overexpression of MCAM induced by SMYD2-H3K36me2 in breast cancer stem cell properties.
    Breast Cancer. 2022 May 12. pii: 10.1007/s12282-022-01365.
    >> Share

  209. HO PJ, Khng AJ, Tan BK, Tan EY, et al
    Relevance of the MHC region for breast cancer susceptibility in Asians.
    Breast Cancer. 2022 May 11. pii: 10.1007/s12282-022-01366.
    >> Share

  210. RUIDAS B, Sur TK, Das Mukhopadhyay C, Sinha K, et al
    Quercetin: a silent retarder of fatty acid oxidation in breast cancer metastasis through steering of mitochondrial CPT1.
    Breast Cancer. 2022 May 5. pii: 10.1007/s12282-022-01356.
    >> Share

  211. NARA M, Ishihara S, Kitano A, Tamura N, et al
    Does breast-conserving surgery with radiotherapy in BRCA-mutation carriers significantly increase ipsilateral breast tumor recurrence? A systematic review and meta-analysis.
    Breast Cancer. 2022;29:394-401.
    >> Share

  212. HIRATA M, Toda H, Higo N, Shinden Y, et al
    Modification of oncoplastic breast surgery with immediate volume replacement using a thoracodorsal adipofascial flap.
    Breast Cancer. 2022;29:531-540.
    >> Share

  213. NASIF D, Real S, Roque M, Branham MT, et al
    CDC42 as an epigenetic regulator of ID4 in triple-negative breast tumors.
    Breast Cancer. 2022;29:562-573.
    >> Share

  214. GRUNTKEMEIER L, Khurana A, Bischoff FZ, Hoffmann O, et al
    Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray-HER2-FISH workflow.
    Breast Cancer. 2022;29:487-497.
    >> Share

  215. GAO P, Wang X, Bai P, Kong X, et al
    Clinical outcomes and patient satisfaction with the use of biological and synthetic meshes in one-stage implant-based breast reconstruction.
    Breast Cancer. 2022;29:450-457.
    >> Share

    April 2022
  216. MONSIVAIS P, Amiri S, Robison J, Pflugeisen C, et al
    Correction to: Racial and socioeconomic inequities in breast cancer screening before and during the COVID-19 pandemic: analysis of two cohorts of women 50 years + .
    Breast Cancer. 2022 Apr 30. pii: 10.1007/s12282-022-01361.
    >> Share

  217. KIKAWA Y, Kotake T, Tsuyuki S, Kang Y, et al
    Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study.
    Breast Cancer. 2022 Apr 23. pii: 10.1007/s12282-022-01357.
    >> Share

  218. BLATNIK A, Ribnikar D, Setrajcic Dragos V, Novakovic S, et al
    BAP1-defficient breast cancer in a patient with BAP1 cancer syndrome.
    Breast Cancer. 2022 Apr 5. pii: 10.1007/s12282-022-01354.
    >> Share

  219. MONSIVAIS P, Amiri S, Robison J, Pflugeisen C, et al
    Racial and socioeconomic inequities in breast cancer screening before and during the COVID-19 pandemic: analysis of two cohorts of women 50 years + .
    Breast Cancer. 2022 Apr 2. pii: 10.1007/s12282-022-01352.
    >> Share

    March 2022
  220. HENG YJ, Love S, DeHart JC, Fingeroth JD, et al
    The association of infectious mononucleosis and invasive breast cancer in The Health of Women (HOW) Study((R)).
    Breast Cancer. 2022 Mar 26. pii: 10.1007/s12282-022-01351.
    >> Share

  221. TERADA M, Miyashita M, Kumamaru H, Miyata H, et al
    Surgical treatment trends and identification of primary breast tumors after surgery in occult breast cancer: a study based on the Japanese National Clinical Database-Breast Cancer Registry.
    Breast Cancer. 2022 Mar 22. pii: 10.1007/s12282-022-01348.
    >> Share

  222. PINTO CS, Peleteiro B, Pinto CA, Osorio F, et al
    Initial experience with targeted axillary dissection after neoadjuvant therapy in breast cancer patients.
    Breast Cancer. 2022 Mar 19. pii: 10.1007/s12282-022-01349.
    >> Share

  223. FICARRA S, Thomas E, Bianco A, Gentile A, et al
    Impact of exercise interventions on physical fitness in breast cancer patients and survivors: a systematic review.
    Breast Cancer. 2022 Mar 12. pii: 10.1007/s12282-022-01347.
    >> Share

  224. JUNJUN S, Yangyanqiu W, Jing Z, Jie P, et al
    Prognostic model based on six PD-1 expression and immune infiltration-associated genes predicts survival in breast cancer.
    Breast Cancer. 2022 Mar 1. pii: 10.1007/s12282-022-01344.
    >> Share

  225. JAMSHIDI F, Farzad M, MacDermid JC, Varahra A, et al
    Assessing the content based on ICF and quality based on COSMIN criteria of patient-reported outcome measures of functioning in breast cancer survivors: a systematic review.
    Breast Cancer. 2022 Mar 1. pii: 10.1007/s12282-022-01340.
    >> Share

  226. OKAZAKI M, Muguruma M, Komiya T, Miyahara K, et al
    Beneficial effects of transdermal administration of tamoxifen on capsular contracture after breast implantation in murine models.
    Breast Cancer. 2022;29:343-351.
    >> Share

  227. ZELLINGER B, Bodenhofer U, Englander IA, Kronberger C, et al
    Hsa-miR-3651 could serve as a novel predictor for in-breast recurrence via FRMD3.
    Breast Cancer. 2022;29:274-286.
    >> Share

  228. BERNINI M, Meattini I, Saieva C, Becherini C, et al
    Pre-pectoral breast reconstruction: early and long-term safety evaluation of 146 unselected cases of the early pre-pectoral era of a single-institution, including cases with previous breast irradiation and post-mastectomy radiation therapy.
    Breast Cancer. 2022;29:302-313.
    >> Share

  229. FAULKNER HR, Coopey SB, Liao EC, Specht M, et al
    The safety of performing breast reconstruction during the COVID-19 pandemic.
    Breast Cancer. 2022;29:242-246.
    >> Share

    February 2022
  230. YUEN S, Monzawa S, Gose A, Yanai S, et al
    Impact of background parenchymal enhancement levels on the diagnosis of contrast-enhanced digital mammography in evaluations of breast cancer: comparison with contrast-enhanced breast MRI.
    Breast Cancer. 2022 Feb 26. pii: 10.1007/s12282-022-01345.
    >> Share

  231. KONISHI T, Fujiogi M, Michihata N, Kumazawa R, et al
    Interstitial lung disorders following postoperative radiotherapy with concurrent or sequential hormonal therapy for breast cancer: a nationwide database study in Japan.
    Breast Cancer. 2022 Feb 26. pii: 10.1007/s12282-022-01346.
    >> Share

  232. LEINERT E, Schwentner L, Janni W, Wockel A, et al
    Outcome analysis of primary breast cancer patients who declined adjuvant chemotherapy-results from the prospective multi-center BRENDA II study.
    Breast Cancer. 2022 Feb 18. pii: 10.1007/s12282-021-01321.
    >> Share

  233. YUAN B, Liu W, Huo M, Zhang J, et al
    The hub ten gene-based risk score system using RNA m(6)A methylation regulator features and tumor immune microenvironment in breast cancer.
    Breast Cancer. 2022 Feb 16. pii: 10.1007/s12282-022-01341.
    >> Share

  234. LOPEZ C, Bosch R, Korzynska A, Garcia-Rojo M, et al
    CD68 and CD83 immune populations in non-metastatic axillary lymph nodes are of prognostic value for the survival and relapse of breast cancer patients.
    Breast Cancer. 2022 Feb 8. pii: 10.1007/s12282-022-01336.
    >> Share

  235. DIEHM YF, Marstaller K, Seckler AM, Berger MR, et al
    The collagenase of the bacterium Clostridium histolyticum does not favor metastasis of breast cancer.
    Breast Cancer. 2022 Feb 7. pii: 10.1007/s12282-022-01337.
    >> Share

    January 2022
  236. ZAREIE B, Rasouli MA, Poorolajal J
    Risk of primary lung cancer after breast cancer radiotherapy: a systematic review and meta-analysis.
    Breast Cancer. 2022 Jan 28. pii: 10.1007/s12282-021-01318.
    >> Share

  237. DASHTI F, Soltani S, Benisi-Kohansal S, Azadbakht L, et al
    Consumption of dairy products and odds of breast cancer: an Iranian case-control study.
    Breast Cancer. 2022 Jan 27. pii: 10.1007/s12282-021-01317.
    >> Share

  238. YANG A, Wu M, Ni M, Zhang L, et al
    A risk scoring system based on tumor microenvironment cells to predict prognosis and immune activity in triple-negative breast cancer.
    Breast Cancer. 2022 Jan 21. pii: 10.1007/s12282-021-01326.
    >> Share

  239. YANG ZY, Yin SP, Ren Q, Lu DW, et al
    BAHD1 serves as a critical regulator of breast cancer cell proliferation and invasion.
    Breast Cancer. 2022 Jan 19. pii: 10.1007/s12282-022-01333.
    >> Share

  240. ZENG Q, Lin X, Chen H, Yan Y, et al
    Multi-time scale transcriptomic analysis on the dynamic process of tamoxifen resistance development in breast cancer cell lines.
    Breast Cancer. 2022 Jan 18. pii: 10.1007/s12282-021-01325.
    >> Share

  241. GU JH, He C, Zhao QY, Jiang TA, et al
    Usefulness of new shear wave elastography in early predicting the efficacy of neoadjuvant chemotherapy for patients with breast cancer: where and when to measure is optimal?
    Breast Cancer. 2022 Jan 17. pii: 10.1007/s12282-021-01327.
    >> Share

  242. MORITA M, Shimomura A, Tokuda E, Horimoto Y, et al
    Is adjuvant chemotherapy necessary in older patients with breast cancer?
    Breast Cancer. 2022 Jan 15. pii: 10.1007/s12282-021-01329.
    >> Share

  243. CARRETTI G, Mirandola D, Maestrini F, Sequi L, et al
    Quality of life improvement in breast cancer survivors affected by upper limb lymphedema through a novel multiperspective physical activity methodology: a monocentric pilot study.
    Breast Cancer. 2022 Jan 13. pii: 10.1007/s12282-021-01322.
    >> Share

  244. UDDIN MN, Wang X
    Identification of key tumor stroma-associated transcriptional signatures correlated with survival prognosis and tumor progression in breast cancer.
    Breast Cancer. 2022 Jan 12. pii: 10.1007/s12282-022-01332.
    >> Share

  245. ABDELRAZEK MA, Nageb A, Barakat LA, Abouzid A, et al
    BC-DETECT: combined detection of serum HE4 and TFF3 improves breast cancer diagnostic efficacy.
    Breast Cancer. 2022 Jan 7. pii: 10.1007/s12282-021-01328.
    >> Share

  246. HAILEY V, Rojas-Garcia A, Kassianos AP
    A systematic review of behaviour change techniques used in interventions to increase physical activity among breast cancer survivors.
    Breast Cancer. 2022 Jan 6. pii: 10.1007/s12282-021-01323.
    >> Share

  247. NIMBI FM, Magno S, Agostini L, Di Micco A, et al
    Sexuality in breast cancer survivors: sexual experiences, emotions, and cognitions in a group of women under hormonal therapy.
    Breast Cancer. 2022 Jan 6. pii: 10.1007/s12282-021-01320.
    >> Share

  248. SUETA A, Yamamoto-Ibusuki M, Tomiguchi M, Fujiki Y, et al
    Predictive and prognostic significance of BRCAness in HER2-negative breast cancer.
    Breast Cancer. 2022 Jan 5. pii: 10.1007/s12282-021-01319.
    >> Share

    November 2021
  249. SU SY
    Nationwide mammographic screening and breast cancer mortality in Taiwan: an interrupted time-series analysis.
    Breast Cancer. 2021 Nov 26. pii: 10.1007/s12282-021-01315.
    >> Share

  250. MUKAND NH, Ko NY, Nabulsi NA, Hubbard CC, et al
    The association between physical health-related quality of life, physical functioning, and risk of contralateral breast cancer among older women.
    Breast Cancer. 2021 Nov 19. pii: 10.1007/s12282-021-01309.
    >> Share

  251. EVANS A, Sim YT, Lawson B, Macaskill J, et al
    The value of prognostic ultrasound features of breast cancer in different molecular subtypes with a focus on triple negative disease.
    Breast Cancer. 2021 Nov 15. pii: 10.1007/s12282-021-01311.
    >> Share

  252. VAN EGDOM LSE, de Ligt KM, de Munck L, Koppert LB, et al
    Predictors of delayed breast reconstruction in the Netherlands: a 5-year follow-up study in stage I-III breast cancer patients.
    Breast Cancer. 2021 Nov 15. pii: 10.1007/s12282-021-01313.
    >> Share

  253. WANG C, Lin Y, Zhu H, Zhou Y, et al
    Breast-conserving therapy for breast cancer with BRCA mutations: a meta-analysis.
    Breast Cancer. 2021 Nov 11. pii: 10.1007/s12282-021-01312.
    >> Share

  254. MAROUFI NF, Rashidi M, Vahedian V, Jahanbazi R, et al
    Effect of Apatinib plus melatonin on vasculogenic mimicry formation by cancer stem cells from breast cancer cell line.
    Breast Cancer. 2021 Nov 1. pii: 10.1007/s12282-021-01310.
    >> Share

  255. LI X, Lin M, Xu J, Pang Y, et al
    New variant of breast-invasive lobular carcinoma with solid and encapsulated papillary carcinoma growth pattern.
    Breast Cancer. 2021;28:1383-1388.
    >> Share

  256. KOTOULA V, Papadopoulou K, Tikas I, Fostira F, et al
    Follow-up of tissue genomics in BRCA1/2 carriers who underwent prophylactic surgeries.
    Breast Cancer. 2021;28:1367-1382.
    >> Share

  257. TANG X, Nakanishi Y, Kobayashi H, Nishimaki H, et al
    Mixed ductal-lobular carcinoma: an analysis of CDH1 DNA copy number variation and mutation.
    Breast Cancer. 2021;28:1318-1327.
    >> Share

  258. SIEGWART LC, Fischer S, Diehm YF, Heil JM, et al
    The transverse musculocutaneous gracilis flap for autologous breast reconstruction: focus on donor site morbidity.
    Breast Cancer. 2021;28:1273-1282.
    >> Share

  259. YOSHIDA R
    Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis.
    Breast Cancer. 2021;28:1167-1180.
    >> Share

  260. TAKAHAMA N, Tozaki M, Ohgiya Y
    Current status of MRI-guided vacuum-assisted breast biopsy in Japan.
    Breast Cancer. 2021;28:1188-1194.
    >> Share

  261. TOZAKI M, Nakamura S
    Current status of breast cancer screening in high-risk women in Japan.
    Breast Cancer. 2021;28:1181-1187.
    >> Share

    October 2021
  262. VEGUNTA S, Bhatt AA, Choudhery SA, Pruthi S, et al
    Identifying women with increased risk of breast cancer and implementing risk-reducing strategies and supplemental imaging.
    Breast Cancer. 2021 Oct 19. pii: 10.1007/s12282-021-01298.
    >> Share

  263. YOTSUMOTO D, Sagara Y, Kumamaru H, Niikura N, et al
    Trends in adjuvant therapy after breast-conserving surgery for ductal carcinoma in situ of breast: a retrospective cohort study using the National Breast Cancer Registry of Japan.
    Breast Cancer. 2021 Oct 19. pii: 10.1007/s12282-021-01307.
    >> Share

  264. TAKAHASHI M, Tokunaga E, Mori J, Tanizawa Y, et al
    Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
    Breast Cancer. 2021 Oct 18. pii: 10.1007/s12282-021-01295.
    >> Share

  265. ROBERTS S, Rojas A, DiRaimo G, Orlando M, et al
    Defer surgery in operable breast cancer: how long is too long?
    Breast Cancer. 2021 Oct 18. pii: 10.1007/s12282-021-01302.
    >> Share

  266. DIAZ-ROLDAN J, Eguia-Larrea M, Rubio-Sanchez T, Munoz-Bellvis L, et al
    Systematic review of synchronous contralateral axillary metastases in breast cancer: really M1 disease?
    Breast Cancer. 2021 Oct 15. pii: 10.1007/s12282-021-01293.
    >> Share

  267. OZAKI A, Tachibana K, Ohtake T
    Correction to: Challenges and future directions in breast cancer care in Fukushima prefecture in Japan: correspondence to "A survey on the current status of clinical resources for diagnosis and treatment of breast cancer in rural hospitals of the Toho
    Breast Cancer. 2021 Oct 13. pii: 10.1007/s12282-021-01306.
    >> Share

  268. LI B, Cheng X, Zhu Y, Wan H, et al
    FOXA1 of regulatory variant associated with risk of breast cancer through allele-specific enhancer in the Chinese population.
    Breast Cancer. 2021 Oct 11. pii: 10.1007/s12282-021-01305.
    >> Share

  269. LEBOK P, Bonte H, Kluth M, Moller-Koop C, et al
    6q deletion is frequent but unrelated to patient prognosis in breast cancer.
    Breast Cancer. 2021 Oct 8. pii: 10.1007/s12282-021-01301.
    >> Share

  270. HORISAWA N, Adachi Y, Takatsuka D, Nozawa K, et al
    The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status.
    Breast Cancer. 2021 Oct 7. pii: 10.1007/s12282-021-01303.
    >> Share

    September 2021
  271. NOGUCHI M, Inokuchi M, Yokoi-Noguchi M, Morioka E, et al
    The involvement of axillary reverse mapping nodes in patients with clinically node-negative breast cancer.
    Breast Cancer. 2021 Sep 30. pii: 10.1007/s12282-021-01300.
    >> Share

  272. TAIRA N, Kashiwabara K, Tsurutani J, Kitada M, et al
    Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.
    Breast Cancer. 2021 Sep 25. pii: 10.1007/s12282-021-01296.
    >> Share

  273. KOH SJ, Ohsumi S, Takahashi M, Fukuma E, et al
    Correction to: Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analys
    Breast Cancer. 2021 Sep 25. pii: 10.1007/s12282-021-01299.
    >> Share

  274. MORI N, Abe H, Mugikura S, Miyashita M, et al
    Discriminating low-grade ductal carcinoma in situ (DCIS) from non-low-grade DCIS or DCIS upgraded to invasive carcinoma: effective texture features on ultrafast dynamic contrast-enhanced magnetic resonance imaging.
    Breast Cancer. 2021;28:1141-1153.
    >> Share

  275. NAKASHIMA K, Uematsu T, Harada TL, Takahashi K, et al
    Can breast MRI and adjunctive Doppler ultrasound improve the accuracy of predicting pathological complete response after neoadjuvant chemotherapy?
    Breast Cancer. 2021;28:1120-1130.
    >> Share

    July 2021
  276. MINEMURA H, Takagi K, Sato A, Yamaguchi M, et al
    Isoforms of IDH in breast carcinoma: IDH2 as a potent prognostic factor associated with proliferation in estrogen-receptor positive cases.
    Breast Cancer. 2021;28:915-926.
    >> Share

  277. TOZAKI M, Yabuuchi H, Goto M, Sasaki M, et al
    Effects of gadobutrol on background parenchymal enhancement and differential diagnosis between benign and malignant lesions in dynamic magnetic resonance imaging of the breast.
    Breast Cancer. 2021;28:927-936.
    >> Share

  278. TENG X, Hayashida T, Murata T, Nagayama A, et al
    A transposon screen identifies enhancement of NF-kappaB pathway as a mechanism of resistance to eribulin.
    Breast Cancer. 2021;28:884-895.
    >> Share

  279. TANAKA K, Masuda N, Hayashi N, Sagara Y, et al
    Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort study.
    Breast Cancer. 2021;28:896-903.
    >> Share

  280. XU C, Gu Z, Liu J, Lin X, et al
    Adenosquamous carcinoma of the breast: a population-based study.
    Breast Cancer. 2021;28:848-858.
    >> Share

    May 2021
  281. MEHRAJ U, Qayoom H, Mir MA
    Prognostic significance and targeting tumor-associated macrophages in cancer: new insights and future perspectives.
    Breast Cancer. 2021;28:539-555.
    >> Share

  282. AKASHI M, Yamaguchi R, Kusano H, Yamaguchi M, et al
    ER staining levels affect HER2 staining and heterogeneity.
    Breast Cancer. 2021;28:720-726.
    >> Share

  283. ZHANG R, Gao P, Han Y, Zhang R, et al
    Reliable assessment of BRCA1 and BRCA2 germline variants by next-generation sequencing: a multicenter study.
    Breast Cancer. 2021;28:672-683.
    >> Share

  284. JIA M, Liao N, Chen B, Zhang G, et al
    PIK3CA somatic alterations in invasive breast cancers: different spectrum from Caucasians to Chinese detected by next generation sequencing.
    Breast Cancer. 2021;28:644-652.
    >> Share

    March 2021
  285. MCMULLEN ER, Skala SL, Gonzalez ME, Djomehri S, et al
    Subcellular localization of EZH2 phosphorylated at T367 stratifies metaplastic breast carcinoma subtypes.
    Breast Cancer. 2021;28:496-505.
    >> Share

  286. MAEDA H, Hayashida T, Watanuki R, Kikuchi M, et al
    Predictors of invasive disease in patients preoperatively diagnosed with ductal carcinoma without stromal invasion, with breast magnetic resonance imaging (MRI) and ultrasound (US).
    Breast Cancer. 2021;28:398-404.
    >> Share

  287. CORADINI D, Gambazza S, Oriana S, Ambrogi F, et al
    Gene expression profile of normal breast tissue and body mass index.
    Breast Cancer. 2021;28:488-495.
    >> Share

  288. FILIPE MD, Simons JM, Moeliker L, Waaijer L, et al
    Patient-reported outcomes of ductoscopy procedures for pathologic nipple discharge.
    Breast Cancer. 2021;28:471-477.
    >> Share

  289. VERDE F, Vigliar E, Romeo V, Campanino MR, et al
    Breast implant associated anaplastic large cell lymphoma (BIA-ALCL): a challenging cytological diagnosis with hybrid PET/MRI staging and follow-up.
    Breast Cancer. 2021;28:527-532.
    >> Share

  290. KUMARI K, Kumar S, Parida DK, Mishra SK, et al
    EZH2 knockdown in tamoxifen-resistant MCF-7 cells unravels novel targets for regaining sensitivity towards tamoxifen.
    Breast Cancer. 2021;28:355-367.
    >> Share

  291. GLASGOW A, Sechrist H, Bomeisl P, Gilmore H, et al
    Correlation between modified Magee equation-2 and Oncotype-Dx recurrence scores using both traditional and TAILORx cutoffs and the clinical application of the Magee Decision Algorithm: a single institutional review.
    Breast Cancer. 2021;28:321-328.
    >> Share

  292. CARRARA GFA, Evangelista AF, Scapulatempo-Neto C, Abrahao-Machado LF, et al
    Analysis of RPL37A, MTSS1, and HTRA1 expression as potential markers for pathologic complete response and survival.
    Breast Cancer. 2021;28:307-320.
    >> Share

  293. ZHAO JM, An Q, Sun CN, Li YB, et al
    Prognostic factors for breast cancer patients with T1-2 tumors and 1-3 positive lymph nodes and the role of postmastectomy radiotherapy in these patients.
    Breast Cancer. 2021;28:298-306.
    >> Share

  294. VUKSANOVIC D, Sanmugarajah J, Lunn D, Sawhney R, et al
    Unmet needs in breast cancer survivors are common, and multidisciplinary care is underutilised: the Survivorship Needs Assessment Project.
    Breast Cancer. 2021;28:289-297.
    >> Share

  295. ALATAWI Y, Hansen RA, Chou C, Qian J, et al
    The impact of cognitive impairment on survival and medication adherence among older women with breast cancer.
    Breast Cancer. 2021;28:277-288.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016